Get Adobe Flash player

Novo Nordisk A/S [Newsroom]
Munich (ots/PRNewswire) – This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today announced that semaglutide, an investigational glucagon-like peptide-1 (GLP-1) … Lesen Sie hier weiter…

Original-Content von: Novo Nordisk A/S, übermittelt durch news aktuell

Powered by WPeMatico

Kommentare sind geschlossen.